Xilio Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.14 Insider Own7.40% Shs Outstand27.40M Perf Week41.79%
Market Cap105.28M Forward P/E- EPS next Y-2.61 Insider Trans0.00% Shs Float25.44M Perf Month66.81%
Income-85.50M PEG- EPS next Q-0.82 Inst Own67.90% Short Float / Ratio0.08% / 0.40 Perf Quarter79.64%
Sales- P/S- EPS this Y-37.30% Inst Trans-6.06% Short Interest0.02M Perf Half Y36.90%
Book/sh4.61 P/B0.86 EPS next Y16.30% ROA-45.60% Target Price9.75 Perf Year-72.26%
Cash/sh5.25 P/C0.76 EPS next 5Y- ROE-55.00% 52W Range1.95 - 14.86 Perf YTD47.58%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-73.28% Beta-
Dividend %- Quick Ratio8.40 Sales past 5Y- Gross Margin- 52W Low103.59% ATR0.39
Employees78 Current Ratio8.40 Sales Q/Q- Oper. Margin- RSI (14)72.75 Volatility17.44% 11.99%
OptionableNo Debt/Eq0.08 EPS Q/Q-18.50% Profit Margin- Rel Volume2.50 Prev Close4.28
ShortableYes LT Debt/Eq0.04 Earnings- Payout- Avg Volume48.13K Price3.97
Recom1.80 SMA2034.73% SMA5051.59% SMA20039.76% Volume120,088 Change-7.24%
Dec-21-22Initiated Chardan Capital Markets Buy $7
Jan-10-22Initiated H.C. Wainwright Buy $36
Nov-16-21Initiated Raymond James Outperform $31
Nov-16-21Initiated Morgan Stanley Overweight $32
Nov-16-21Initiated Guggenheim Buy $40
Nov-16-21Initiated Cowen Outperform
Jan-26-23 05:30AM
Jan-25-23 09:45AM
Nov-23-22 07:30AM
Nov-09-22 07:30AM
Nov-04-22 07:30AM
04:05PM Loading…
Sep-22-22 04:05PM
Sep-15-22 04:05PM
Sep-06-22 04:05PM
Aug-11-22 09:41AM
Aug-09-22 07:30AM
Jun-16-22 07:30AM
May-18-22 07:30AM
May-17-22 07:30AM
May-12-22 07:30AM
Apr-07-22 06:30AM
06:30AM Loading…
Mar-01-22 06:30AM
Feb-28-22 06:30AM
Feb-07-22 05:38PM
Feb-03-22 06:30AM
Jan-25-22 10:27AM
Jan-20-22 07:30AM
Jan-06-22 07:30AM
Dec-02-21 07:30AM
Nov-12-21 07:00AM
Oct-27-21 07:45AM
Oct-26-21 04:05PM
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.